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Dipyridamole in Hypertriglyceridemia
IKUO YOKOYAMA, MD, TOHRU OHTAKE, MD, SHIN-ICHI MOMOMURA, MD,
KATSUNORI YONEKURA, MD, JUNICHI NISHIKAWA, MD, YASUHITO SASAKI, MD,
MASAO OMATA, MD
Tokyo, Japan
Objectives. This study sought to investigate the specific role of
hypertriglyceridemia in the myocardial hyperemic stress with
dipyridamole/rest flow ratio (MDR).
Background. Reduced MDR has been reported in hypercholes-
terolemic patients without evidence of ischemia. However, the
specific role of hypertriglyceridemia in MDR has not been studied.
Methods. Fifteen nondiabetic normocholesterolemic hypertri-
glyceridemic patients and 13 age-matched control subjects were
studied. Myocardial blood flow (MBF) during dipyridamole ad-
ministration and baseline MBF in hypertriglyceridemic patients
and control subjects were measured using positron emission
tomography and nitrogen-13 ammonia, after which the MDR was
calculated.
Results. Baseline MBF (ml/min per 100 g heart weight) in
hypertriglyceridemic patients (mean 6 SD 73.6 6 24.1) did not
differ significantly from that in control subjects (81.6 6 37.2).
MBF during dipyridamole loading in hypertriglyceridemic pa-
tients (198 6 106) was significantly reduced compared with that in
control subjects (313 6 176, p < 0.05), as was the MDR (2.71 6
1.07 vs. 3.73 6 1.14, respectively, p < 0.05). Spearman rank-order
correlation analysis showed a significant relation between plasma
triglyceride concentration and MDR (r 5 20.466, asymptotic SE
0.157, p 5 0.0125); however, no such significant relation was seen
between total plasma cholesterol concentration and MDR (r 5
20.369, asymptotic SE 0.130, p 5 0.059).
Conclusions. Impaired myocardial vasodilation was suggested
in hypertriglyceridemic patients without symptoms and signs of
ischemia.
(J Am Coll Cardiol 1998;31:1568–74)
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A relation between the myocardial hyperemic stress/rest flow
ratio and coronary stenosis has been shown (1). However,
contradictory results have also been reported (2), which indi-
cates that this issue remains controversial. Furthermore, recent
clinical investigations have shown alterations in the myocardial
hyperemic stress with dipyridamole/rest flow ratio (MDR)
before the progression of typical symptoms or signs of coro-
nary artery disease (CAD) in association with several coronary
risk factors, including hypercholesterolemia (3–5) and diabetes
(6–8). Therefore, early progression of coronary atherosclero-
sis or abnormal myocardial vasodilation was suggested in high
risk subjects for CAD without evidence of CAD.
Although hypertriglyceridemia has been suggested as a risk
factor for CAD (4,9–12), and its atherogenicity has also been
reported (13–23), the specific effect of hypertriglyceridemia on
MDR has not been investigated. The present study aimed to
clarify whether MDR is reduced in hypertriglyceridemic pa-
tients without symptoms and signs of CAD.
Methods
Study cohort. Fifteen nondiabetic normocholesterolemic
hypertriglyceridemic (NCHTG) patients (11 men, 4 women)
and 13 normolipidemic normoglycemic asymptomatic healthy
subjects without a history of heart or chronic disease (control
subjects) (nine men, four women) were studied. No subject had
evidence of ischemia, and the results of the rest electrocardio-
gram (ECG) and symptom-limited treadmill tests were normal.
No subject was taking oral lipid-lowering agents. Selected for
this study were NCHTG patients with total plasma cholesterol
,5.7 mmol/liter (220 mg/dl) and plasma triglycerides .2.2
mmol/liter [200 mg/dl] range 2.2 to 12.3 mmol/liter) after a
14-h fast. Four hypertensive patients who were well controlled
with medication and two borderline hypertensive hypertriglyc-
eridemic patients were included in the NCHTG group. To
ensure the diagnostic accuracy of fasting hypertriglyceridemia,
patients with less severe hypertriglyceridemia (1.8 to 2.2 mmol/
liter) were not included in the study to avoid diagnostic error.
Intake of caffeine and medications was prohibited 24 h before
positron emission tomography (PET). The general character-
istics of the study subjects are summarized in Table 1. There
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were no significant differences in age, gender, body weight,
height, body mass index, blood pressure, smoking habits or
hemoglobin A1c levels among the two groups. All study
subjects were informed of the nature of the study, after which
they agreed to participate in the protocol, which was approved
by the local ethics committee. Because of difficulty in obtaining
PET data for normal subjects, 9 control subjects were common
to two previous studies (5,8) and 10 to a third study (3).
Regional myocardial blood flow (MBF) (ml/min per 100 g)
at rest and during dipyridamole administration was measured
using PET and nitrogen-13 (N-13) ammonia. PET data were
obtained using a Headtome IV scanner (Shimadzu Corp.,
Kyoto, Japan). This PET scanner has seven imaging planes;
in-plane resolution is 4.5 mm at full-width half-maximum, and
the z-axial resolution is 9.5 mm at full-width half-maximum.
Effective in-plane resolution was 7 mm after using a smoothing
filter. The sensitivities of the Headtome IV are 14 and 24 kcps
(kilo counts per second) for direct and cross-planes, respec-
tively.
After acquisition of transmission data to correct for photon
attenuation before obtaining the PET images, 15 to 20 mCi of
N-13 ammonia was injected, and dynamic PET scanning was
performed for 2 min and static PET for 8 min. After waiting
55 min to allow for decay of the radioactivity of N-13 ammonia
after the initiation of scanning, dipyridamole (0.56 mg/kg body
weight) was loaded intravenously over a 4-min period. Five
min after the end of dipyridamole infusion, 15 to 20 mCi of
N-13 ammonia was injected, and, at exactly the same time,
dynamic PET scanning was again performed for 2 min and
static PET for 8 min. The dynamic PET scan was acquired
every 15 s (eight times) during the 2-min period. Dynamic data
were obtained for seven slices. Only a single-channel ECG in
limb leads was recorded during PET. The precordial ECG was
not monitored because of technical difficulty.
Determination of MBF. Regional MBF was calculated
according to the two-compartment N-13 ammonia tracer ki-
netic model (24,25). The time–activity curve of the left ven-
tricular cavity was used as an input function. Tracer spillover
was corrected by least square nonlinear regression analysis on
our program to calculate MBF with the assumption that both
myocardial and left ventricular radioactivity were influenced by
each other. Details were reported in our previously published
reports (3,5).
All data were corrected for deadtime effects to reduce error
to ,1%. To avoid the influence of the partial volume effect
associated with the object’s size, recovery coefficients obtained
from experimental phantom studies in our laboratory were
used. The recovery coefficient was 0.8 when myocardial wall
thickness was 10 mm. For correction of the partial volume
effect, wall thickness was measured with two-dimensional
echocardiography by specialists in our hospital. The recovery
coefficient was taken into consideration in our program to
measure MBF.
To determine MBF, regions of interest were placed at the
septum and anterior, lateral and inferoposterior walls on the
transaxial images, as previously reported (5). To obtain input
function, regions of interest were placed on the left ventricular
cavity of each slice. The average of those regional MBF values
was used to obtain the MDR (the ratio of MBF during dipyrid-
amole administration to baseline MBF). Static N-13 ammonia
images were also obtained from the PET study and analyzed
visually by three independent specialists (T.O., S.M. K.Y. or I.Y.,
T.O., K.Y.) without other information about the patients.
Statistical analysis. Individual data, including baseline
MBF, MBF during dipyridamole administration, MDR, body
weight, systolic blood pressure, diastolic blood pressure,
height, body mass index and lipid variables, between hypertri-
glyceridemic and control subjects were analyzed by the two-
tailed unpaired Student t test. Results are expressed as mean
value 6 SD. Relations between MDR and total cholesterol or
plasma triglycerides were analyzed by the Spearman rank-
order correlation. A p value ,0.05 was considered significant.
Results
Hemodynamic and ECG responses to dipyridamole infu-
sion and exercise stress testing. There were no significant
differences in SBP and rate–pressure product at rest and
Abbreviations and Acronyms
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
FH 5 familial hypercholesterolemia
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
MBF 5 myocardial blood flow
MDR 5 myocardial hyperemic stress with dipyridamole/rest flow
ratio
NCHTG 5 nondiabetic normocholesterolemic hypertriglyceridemic
PET 5 positron emission tomography (tomographic)
SH 5 secondary hypercholesterolemia
Table 1. Clinical Characteristics of Study Subjects
Control
Subjects
(n 5 13)
Hypertriglyceridemic
Patients
(n 5 15)
Age 53.6 6 7.0 53.7 6 11.7
Men/women 9/4 11/4
BW (kg) 62.4 6 5.7 64.4 6 8.5
Ht (m) 1.62 6 7.2 1.60 6 7.9
BMI (kg/m2) 24.2 6 2.2 25.3 6 2.3
Hb A1c (%) 5.7 6 0.33 5.9 6 0.56
Smoking (cigarettes/day) 13.0 6 8.7 14.1 6 11.6
TC (mmol/liter) 5.0 6 0.42 4.9 6 0.55
LDL (mmol/liter) 3.1 6 0.80 2.6 6 0.83
HDL (mmol/liter) 1.4 6 0.34 1.0 6 0.27*
TGs (mmol/liter) 1.4 6 0.42 7.0 6 3.7*
*p , 0.05 versus control group. Data presented are mean value 6 SD or
number of patients. BMI 5 body mass index; BW 5 body weight; Hb A1c 5
hemoglobin A1c; HDL 5 high density lipoprotein cholesterol; Ht 5 height;
LDL 5 low density lipoprotein cholesterol; TC 5 total cholesterol; TG 5
triglycerides.
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during dipyridamole administration between the two groups,
nor were differences significant between the two groups for
rate–pressure product, heart rate and duration of exercise
during exercise stress testing (Table 2). During dipyridamole
administration, typical chest pain or chest discomfort was not
observed in any study subject. Atypical chest pain, chest
discomfort or dyspnea, suggesting side effects of dipyridamole
were observed in two patients and two control subjects without
abnormal changes on the ECG.
Static PET images. Static PET images at rest and during
dipyridamole loading did not show any regional irregular
uptake of N-13 ammonia to significant regional stenotic lesions
in coronary arteries.
MBF. Baseline MBF (ml/min per 100 g weight heart) in the
NCHTG group (73.6 6 24.1) was not different from that in the
control group (81.6 6 37.2, p 5 0.5005) (Fig. 1, top). MBF
during dipyridamole administration in the NCHTG group
(198 6 106) was significantly reduced compared with that in
the control group (313 6 176, p 5 0.0437) (Fig. 1, middle).
MDR. MDR in the NCHTG group (2.71 6 1.07) was
significantly lower than that in the control group (3.73 6 1.14,
p 5 0.021 (Fig. 1, bottom). There was no significant difference
in MDR between normotensive patients (2.87 6 1.09) and
those with hypertension or borderline hypertension (2.42 6
1.09, p 5 0.472). There were no significant regional differences
in MDR in either the NCHTG or the control group (Table 3).
No gender-specific differences in MDR were seen in either
the NCHTG group (men 2.52 6 1.00, women 2.85 6 1.51, p 5
0.628) or the control groups (men 3.34 6 1.11, women 4.23 6
1.07, p 5 0.1843).
Relation between plasma lipid fractions. Spearman rank-
order correlation analysis showed a significant relation be-
tween plasma triglyceride concentration and MDR (r 5
20.466, asymptotic SE 0.157, p 5 0.0125) (Fig. 2, top);
however, no such significant relation was seen between total
plasma cholesterol concentration and MDR (r 5 20.361,
asymptotic SE 0.130, p 5 0.059) (Fig. 2, bottom). Neither low
density lipoprotein (LDL) cholesterol nor high density lipopro-
tein (HDL) cholesterol concentration correlated with MDR.
Table 2. Hemodynamic Responses to Dipyridamole and Exercise
Stress Testing
Control
Subjects
(mean 6 SD)
Hypertriglyceridemic
Patients
(mean 6 SD)
SBP 126 6 8.5 143 6 40.0
DBP 75.0 6 6.8 81.8 6 20.0
Rest
HR 69.6 6 11.1 73.4 6 12.8
RPP 8,709 6 1,438 10,490 6 1,847
Dipyridamole
SBP 121 6 16.2 139.8 6 29.8
DBP 77.6 6 6.8 87.9 6 19.1
HR 83.1 6 19.3 78.4 6 14.6
RPP 10,161 6 1,685 12,288 6 2,269
Exercise
HR 138.8 6 21.4 141.3 6 18.4
SBP 167.9 6 24.99 166.3 6 21.3
RPP 23,399 6 5,293 23,498 6 3,067
Duration (s) 446 6 113 478 6 128
DBP 5 diastolic blood pressure (mm Hg); HR 5 heart rate (beats/min);
RPP 5 rate–pressure product (beats/min 3 mm Hg); SBP 5 systolic blood
pressure (mm Hg).
Figure 1. MBF at rest (top), during dipyridamole (DP) administration
(middle) and MDR (bottom) in control subjects versus hypertriglyc-
eridemic patients. Individual subject data are shown by open circles,
mean value 6 SD by vertical bars.
Table 3. Comparison of Regional MDR in Each Region of Interest
MDR (mean 6 SD)
Septum
Anterior
Wall
Lateral
Wall
Posterior
Wall
Control subjects 3.85 6 1.35* 3.77 6 1.53* 3.61 6 1.21* 3.74 6 1.33*
HTG patients 2.83 6 1.24 2.74 6 1.20 2.54 6 1.11 2.70 6 1.18
*p , 0.05 versus hypertriglyceridemic (HTG) patients. MDR 5 myocardial
hyperemic stress with dipyridamole/rest flow ratio.
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Discussion
As shown by Gould and Lipscomb (1), the myocardial
hyperemic stress/rest flow ratio was thought to be a variable
related to coronary atherosclerosis because it decreases in
accordance with severity of coronary stenosis. However, con-
troversial results of another investigation (2) showed that this
relation is not constant. An altered myocardial hyperemic
stress/rest flow ratio was also reported in a variety of coronary
risk factors, such as hypercholesterolemia (3–5) and diabetes
mellitus (6–8,26). However, the specific effect of hypertriglyc-
eridemia on MDR was not investigated.
Although hypertriglyceridemia has been suggested as a risk
factor for CAD from clinical observations (4,9–12), the patho-
physiologic features of hypertriglyceridemia have not been as
well understood nor as thoroughly investigated as those of
hypercholesterolemia (27–34). Recently, insulin resistance has
been proposed as a risk factor for CAD (13). Because insulin
resistance is usually associated with hypertriglyceridemia, the
importance of hypertriglyceridemia has emerged, particularly
in relation to insulin resistance (13–22). However, the patho-
physiology of hypertriglyceridemia, especially with reference to
the specific role of hypertriglyceridemia on MDR, has not been
clarified, although a relation between hypertriglyceridemia and
MDR has been suggested in mixed combined hyperlipidemia
(4). Results of our investigation of MDR in NCHTG patients
showed that MDR was significantly reduced in NCHTG, as has
been suggested in hypercholesterolemia (3–5), and that the
degree of reduction was significantly correlated with fasting
plasma total triglyceride levels. After comparison of our
present results with recently published data, MDR in NCHTG
patients was comparable to that in patients with secondary
hypercholesterolemia (SH) (4,5) and was significantly higher
than that in those with familial hypercholesterolemia (FH) (3).
This finding suggests that the potential risk for coronary
atherosclerosis or atherosclerosis-related myocardial perfusion
abnormality in NCHTG patients without symptoms and signs
of CAD is similar to that of patients with SH.
Possible mechanism for reduced MDR in NCHTG patients.
The results of recent animal studies (22,23) suggest a relation
between atherosclerosis and hypertriglyceridemia in experi-
mentally induced hypertriglyceridemia. Ito et al. (22) devel-
oped human Apo C-III transgenic mice that expressed ele-
vated triglyceride levels (3.1 to 11.2 mmol/liter) with increased
aortic atherosclerotic lesions. Hayek et al. (23) reported that
atherosclerotic lesions could be decreased by the transfer of
the cholesterol ester transfer protein gene only in the aortas of
hypertriglyceridemic mice, although plasma HDL cholesterol
levels were significantly reduced in cholesterol ester transfer
protein transgenic hypertriglyceridemic mice. Low levels of
HDL cholesterol were not related to atherosclerosis in hyper-
triglyceridemia in these animals (23). In our study, plasma
HDL levels did not correlate with MDR, a result consistent
with that of the animal study (23).
Reduced MDR in angiographically normal coronary arter-
ies in hypercholesterolemic patients (5) suggests that such
decreases may also be present in angiographically normal
coronary arteries in NCHTG subjects. With regard to this
issue, Mintz et al. (35) recently demonstrated by evaluation
with intravascular ultrasound the presence of atherosclerotic
lesions in the arterial walls of angiographically normal
coronary arteries. They also showed that angiographically
undetectable atherosclerosis was related to diabetes and hy-
percholesterolemia. In consideration of these findings, angio-
graphically undetectable coronary atherosclerosis can be
another factor for the reduced MDR in NCHTG patients.
The principal pharmacologic action of dipyridamole on
coronary arteries is considered to be endothelial independent.
However, recent animal experimental studies (36,37) suggest
that abnormal endothelial function might also influence the
blood flow response to dipyridamole. Therefore, impaired
flow-mediated vasodilation (endothelial function) may be a
factor in this finding. However, such speculation cannot be
confirmed by our results. Wilson and White (38) and McGinn
et al. (39) reported that there was no significant difference in
coronary flow reserve between papaverine stress loading and
single-dose dipyridamole stress loading when additional ni-
trates were infused over the entire study period. Therefore, it
is not clear whether a single dose of dipyridamole can increase
MBF maximally in normal subjects. For this reason, we used
the term “MDR” rather than coronary flow reserve. Further-
more, it is well known that nitrates dilate coronary conduc-
tance vessels independently of endothelial function but do not
dilate the coronary microcirculation. Therefore, additional
infusions of nitrates would provide more detailed information
Figure 2. Top, Relation between MDR and plasma triglyceride con-
centrations in hypertriglyceridemic and control subjects. There was a
significant negative correlation between the two variables. Bottom,
Relation between MDR and plasma cholesterol concentrations in
hypertriglyceridemic and control subjects. There was no significant
negative correlation between the two variables.
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for interpreting this finding. However, intracoronary nitrate
infusion is required for accurate data collection to avoid
hemodynamic changes. Moreover, side effects, such as severe
headache, nausea and hypotension, would more frequently
occur during maximal vasodilatory stress testing using systemic
administration of nitrates, unlike the intracoronary adminis-
tration of such agents. Such a method would put study subjects
at risk for great discomfort. Therefore, the PET study does
have limitations. Furthermore, the principal aim of our study
was to test the hypothesis that perfusion abnormalities exist in
NCHTG patients without evidence of CAD. Impaired myocar-
dial vasodilation in response to dipyridamole is indicated by
our results, although this finding might represent a myocardial
perfusion abnormality. Because several investigations (38–41)
have shown that single-dose dipyridamole stress could be
expected to cause submaximal MBF, such a hypothesis can be
tested by use of that particular dose. It is not yet clear if the
reduced MDR in our NCHTG subjects was due to insignificant
atherosclerosis, angiographically undetectable atherosclerosis,
coronary microcirculation abnormalities or impaired endothe-
lial function, or a combination of these factors. Future studies
should be directed toward this issue.
Recently, age-related reduction of MDR in normal subjects
was reported (42). In the present study, there was no significant
difference in age between NCHTG patients and control sub-
jects. Therefore, our results were not due to an age-related
reduction in MDR.
The range of HDL cholesterol concentrations among our
study subjects was narrow. It is thus not surprising that a
significant relation was not observed between MDR and
plasma HDL cholesterol concentrations. Furthermore, the
antiatherogenic effect of HDL cholesterol is not directly
related to its concentration but, rather, to its function of HDL.
For example, it has been suggested (43) that subjects with high
HDL levels and a cholesterol ester transfer protein deficit are
at a high risk for CAD, whereas subjects with low HDL levels
and apolipoprotein I Milano rarely develop CAD (44). Other
investigations have shown (23) that the risk of aortic athero-
sclerosis is higher in hypertriglyceridemic mice with normal
HDL cholesterol concentrations than in cholesterol ester
transfer protein gene knockout mice with hypertriglyceridemia
that have high HDL concentrations. These findings may ac-
count for the lack of a significant relation between HDL
concentration and MDR among our subjects.
Gender-specific variance of MDR in NCHTG. We previ-
ously reported (3) a gender-specific variance of MDR in FH.
The incidence of CAD in male patients with FH is significantly
higher than that in female patients with FH, and longevity is
greater for female than for male patients (30). However, in the
present study a gender-specific difference was not seen in
hypertriglyceridemic patients. Because we did not attempt to
differentiate patients with FH from those with SH, it cannot be
ascertained whether the duration of the hypertriglyceridemic
state was sufficient for a gender variance in MDR to become
apparent.
Power results. In the present study, both MBF during
dipyridamole administration and MDR were reduced, but
baseline MBF was not elevated in hypertriglyceridemic pa-
tients. Furthermore, MDR was significantly inversely corre-
lated with plasma triglyceride concentration but not with
plasma total cholesterol, HDL cholesterol or LDL cholesterol
concentrations. The power of these results highly suggest that
myocardial vasodilatory capacity in response to dipyridamole is
impaired by hypertriglyceridemia.
Determination of MBF using PET and N-13 ammonia. We
used the two-compartment N-13 ammonia tracer kinetic model
to determine MBF by means of dynamic PET and N-13
ammonia (24,25). There have been numerous reports on
measurement of MBF by means of N-13 ammonia PET.
Among these, the two-compartment model has been well
validated (3,5,24,25,42,45–62) and used most frequently in
studies of MBF or MDR (3,5,8,24,25,42,48–50,52–62). There-
fore, we used the two-compartment N-13 ammonia model in
our study to assess MBF.
Clinical implications. It has been suggested (61,64) that
reduced MDR in hypertriglyceridemic patients can be im-
proved by lipid-lowering therapy. In view of our findings of
reduced MDR in hypertriglyceridemic patients, it would be
important to investigate whether such a reduction could be
reversed by vigorous control of hypertriglyceridemia, as has
been suggested in studies of hypertriglyceridemic patients
(60–63). This hypothesis warrants further investigation.
Conclusions. MDR was decreased in NCHTG patients
without evidence of CAD. Impaired myocardial vasodilation
and the risk of coronary atherosclerosis in hypertriglyceride-
mia were suggested. Nitrogen-13 ammonia PET is useful for
the management of atherosclerosis in hyperlipidemic subjects,
including hypertriglyceridemic patients.
We thank Tohru Inoue and Yoshio Kojima for technical support in preparing the
N-13 ammonia. We also thank Toshiyuki Moritan for technical support during
the study.
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